In today’s briefing:
- Regarding the Six KRX Sector Names that Ran Ahead of Friday’s Official Review Drop
- Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning
Regarding the Six KRX Sector Names that Ran Ahead of Friday’s Official Review Drop
- Six names stood out with simultaneous volume spikes and sharp pops last Friday; all Semis and Autos additions with big passive impact, while all others showed no tape action.
- Results likely leaked early, prompting front-running on Semis and Autos adds—high passive impact names—causing Friday’s sharp volume and price spikes.
- Early movers are mostly priced in; Thursday momentum plays still work, but Monday–Thursday morning requires caution. Focus on volume-driven flows before loading positions, long-short basket viable for other passive-impact names.
Myungin Pharm Pre-IPO: Discount to Peers; Potential Succession Planning
- Myungin Pharmaceutical (MYUNGIN KS) is looking to raise up to US$142m in its upcoming Korean IPO.
- It specializes in central nervous system (CNS) therapeutics and boasts an extensive product line-up of over 200 CNS products.
- In this note, we examine the IPO dynamics, and look at the firm’s valuation.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
